{
    "eid": "2-s2.0-85152835463",
    "title": "Immunosuppression in kidney transplantation",
    "cover-date": "2016-01-01",
    "subject-areas": [],
    "keywords": [],
    "authors": [
        "Natavudh Townamchai"
    ],
    "citedby-count": 0,
    "ref-count": 29,
    "ref-list": [
        "Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients",
        "Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation",
        "Alemtuzumab induction in renal transplantation",
        "Am J Transplant",
        "Risk Factors of Cytomegalovirus Disease in Kidney Transplant Recipients: A Single-Center Study in Thailand",
        "The effect of low and ultra-low dosages Thymoglobulin on peripheral T, B and NK cells in kidney transplant recipients",
        "Rabbit antithymocyte globulin versus basiliximab in renal transplantation",
        "Interleukin 2 receptor antagonists for kidney transplant recipients.",
        "Therapeutic monitoring of calcineurin inhibitors for the nephrologist",
        "The clinical benefits of cyclosporine C2-level monitoring: A systematic review",
        null,
        "A Simple Novel Technique to Estimate Tacrolimus Dosages during the Early Post Kidney Transplantation Period",
        "The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects",
        "Clinically significant cytochrome P-450 drug interactions- A comment",
        "Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant",
        "Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation",
        "Proteinuria after kidney transplantation",
        "mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes",
        "Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial",
        "Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies",
        "Current development of mTOR inhibitors as anticancer agents",
        "Make yourself at home: Viral hijacking of the PI3K/Akt signaling pathway",
        "Impact of the heterozygous TPMT*1/*3C genotype on azathioprine-induced myelosuppression in kidney transplant recipients in Thailand",
        "Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation",
        "Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: The fixed-dose concentration-controlled trial",
        "Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: The opticept trial",
        "Enteric-Coated Mycophenolate Sodium",
        "Guidelines on the use of therapeutic apheresis in clinical practice - Evidence-based approach from the writing committee of the american society for apheresis: The sixth special issue",
        "Update: Clinically significant cytochrome P-450 drug interactions"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}